Chi-Chung Li

Genentech Roche

Dr. Li is the clinical pharmacology lead in T-cell directed bispecific antibody at Genentech. She has 16 years of experience in quantitative pharmacology research and specializes in clinical drug development (Phase I to IV) of small molecule pharmaceuticals and biologics. She serves as the lead clinical pharmacology representative on cross-functional project teams and leads modeling and simulations efforts to impact the design, execution and interpretation of data from over 90 clinical protocols across multiple therapeutic areas, including cancer immunology, neuroscience, infectious disease, cardiovascular diseases and respiratory/ immunology. Her quantitative background in engineering allows her to effectively integrate across multiple modeling methodologies, including statistical, PK/PD, mechanistic, and systems modeling to impact the decision making in clinical drug development. She has expertise in regulatory interactions and authorship of regulatory documents for U.S. and E.U. filings for adult and pediatric applications.
She currently leads the platform strategy of T-cell dependent bispecific antibodies (TDB) development within clinical pharmacology at Genentech and manages a group of scientists to advance the science to bring this novel class of medicine to patients. She is also actively involved in departmental initiatives as a leader to expand the access and utilization of real-world data in the context of big data analyses to inform personalized medicine.
She earned her bachelor’s degree in chemical engineering from Taiwan University, and her master’s and Ph.D. degrees in chemical engineering from the University of Florida.